EnGene Stock News

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral gene therapy company, today announced its financial results for the third quarter ended July 31, 2025, and provided a business update. “Reaching target enrollment in LEGEND's pivotal Cohort 1 and securing RMAT designation are important milestones that mark our continue...

enGene Holdings Inc. (NASDAQ:ENGN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:50 PM EDT Company Participants Ronald H. Cooper - President, CEO & Director Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst Welcome to the session of the Morgan Stanley Global Healthcare Conference.

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral gene therapy company, today announced it has achieved its target enrollment milestone of 100 patients for the pivotal cohort of its ongoing, open-label, multi-cohort Phase 2 LEGEND trial of detalimogene voraplasmid (“detalimogene” and previously EG-70) in patients with...

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral gene therapy company, today announced that management will participate in the following investor conferences in September: 2025 Wells Fargo Healthcare Conference Date: Wednesday, September 3, 2025 Time: 8:45 a.m. ET H.C. Wainwright 27th Annual Global Investment Conference Date: Monda...

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today reported the grant of inducement equity awards to three newly-hired employees, with a grant date of July 31, 2025. The inducement awards consist of non-qualified stock options to purchase an aggregate 93,200 of the Company's comm...

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced the appointment of three new members to its Board of Directors: Philip Astley-Sparke, William Grossman, M.D., Ph.D., and Michael Heffernan, R.Ph. Their combined experience across gene therapy, oncology, clinical devel...

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid (also known as detalimogene, and previously EG-70), the Company's lea...

enGene Holdings Inc.'s lead asset, detalimogene voraplasmid, continues to show early promise in non-muscle invasive bladder cancer, with pivotal LEGEND trial data expected in late 2025. Financially, ENGN maintains a cash runway into 2027, supporting ongoing development without major liquidity concerns in the near term. While regulatory discussions are encouraging, the investment thesis hinges o...